GET DAILY SIGNALS10x Genomics (TXG) Slides -14% Over 30 Days While Holding +60% Quarterly Gains
Key Takeaways
- 10x Genomics (TXG) shares fell roughly 14% over the past 30 days, sliding from about $85.71 to the mid-$73 level and unwinding part of an extended multi-month rally.
- The decline followed preliminary third-quarter results that missed Wall Street estimates and a cut to full-year revenue guidance, which management attributed to a sales-force reorganization and more cautious customer budgets.
- The short-term pullback contrasts with the broader quarter, where the stock remains sharply higher after climbing from roughly $46 in late July to a peak above $97 in early October.
- Analyst activity turned mixed: Barclays (price target $110), Canaccord ($100), and BofA ($80) raised targets, while J.P. Morgan reiterated a Hold at $70 and Stephens downgraded the stock to Equal Weight at $65.
- Ongoing insider selling, totaling about $16.9 million over the trailing 12 months with no reported purchases, has added to investor caution.
10x Genomics (TXG) Company Overview and Market Position
10x Genomics develops and sells instruments, consumables, and software used to study biological systems at the single-cell and spatial level. Its core product portfolio includes the Chromium single-cell platform, the Visium and Xenium spatial platforms, and the newer Atera spatial-biology instrument, alongside the Sentira cloud analysis platform. These solutions serve academic researchers, translational labs, and biopharmaceutical companies across fields such as oncology, immunology, and neuroscience.
Investors follow TXG because of its leadership position in the high-growth single-cell and spatial genomics tools segment, its recurring consumables revenue model, and the potential of newer platforms to expand its addressable market. The company competes in a competitive life science tools landscape that includes established players such as Illumina (ILMN), while its differentiated focus on spatial biology and multiomics underpins its long-term growth narrative. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
10x Genomics (TXG) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, TXG declined approximately 14%, falling from a closing price of about $85.71 to the mid-$73 range. The stock reached an intraday high near $102.81 in early October before reversing sharply, with much of the decline concentrated in a volatile stretch that began around October 6.
The picture over the last quarter is notably different. Measured over roughly three months, TXG is still up about 60%, having risen from approximately $46 in late July to its current level. This contrast highlights the nature of the recent move: the 30-day decline is a partial retracement of an exceptionally strong multi-month advance rather than a reversal of the longer-term trend.
What Drove TXG Stock Price in the Last 30 Days
The primary catalyst for the recent decline was the company's preliminary third-quarter results, which came in below Wall Street forecasts and showed a modest year-over-year revenue decline. Management also lowered full-year revenue guidance, citing disruption from a sales-force overhaul and more cautious customer budgets. The announcement triggered a sharp single-day selloff and contributed to analyst downgrades and price-target cuts.
The pullback was amplified by profit-taking following a dramatic run-up. Heading into October, TXG had gained several hundred percent over the trailing year, leaving the stock vulnerable to a sharp reversal once the fundamental news softened. Insider selling also weighed on sentiment: corporate insiders sold roughly $16.9 million of stock over the prior 12 months without meaningful buying activity.
Analyst commentary remained divided. Barclays and Canaccord raised their price targets substantially, citing AI-driven demand and utilization trends in life science tools, while BofA lifted its target but kept a Neutral rating. By contrast, J.P. Morgan reiterated a Hold rating, and Stephens downgraded TXG to Equal Weight, reflecting lingering questions about execution and the durability of recent growth. From what I see, this mixed analyst view adds an extra layer of uncertainty worth monitoring.
What Drove TXG Stock Performance Over the Last Quarter
The broader three-month advance was driven by a combination of product momentum and renewed investor enthusiasm for AI-linked life science tools. In late September, the company began shipping its Atera spatial-biology platform, with booked orders reportedly exceeding the systems it expected to deliver in 2026, and it introduced Sentira, a cloud analysis platform expected to become a paid product in early 2027.
Analysts tied much of the rally to rising expectations around AI-driven drug discovery and spatial biology demand, prompting a wave of price-target increases. A research collaboration with Fred Hutchinson Cancer Center and the earlier Scale Biosciences acquisition further reinforced the company's positioning in advanced genomics. The quarter's gains, however, left the stock trading at a substantial premium, and the October guidance revision exposed how quickly sentiment could shift when near-term results disappointed.
TXG Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor the company's next quarterly earnings report and any updated guidance for signs of whether the sales-force transition stabilizes and instrument demand rebounds. The pace of Atera platform shipments and the ramp of Sentira toward commercial monetization will be key indicators of whether the growth narrative can be sustained.
Analyst expectations, consumables pull-through trends, and broader life science funding conditions are also likely to influence the stock. Given the stock's elevated valuation relative to historical multiples and the presence of ongoing operating losses, execution on margin expansion and revenue growth will be central to investor confidence. Macroeconomic factors, sector rotation within growth-oriented equities, and any further regulatory or competitive developments in genomics tools round out the key watch items. I'm watching this closely as the next earnings cycle approaches.
Exploring AI Tools for Deeper Market Insights
In my own research process, I occasionally turn to Tickeron’s AI Trading Bots to see how automated strategies are positioned around names like this. The platform offers a range of bots with different approaches and timeframes, which can provide additional perspective on volatile moves without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TXG in upward trend: price rose above 50-day moving average on October 26, 2026
TXG moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 32 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 39 of 56 cases where TXG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
Following a +4.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where TXG advanced for three days, in 205 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 196 of 232 cases where TXG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for TXG moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 26 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TXG as a result. In 76 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for TXG turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 10-day moving average for TXG crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TXG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.515) is normal, around the industry mean (3.847). P/E Ratio (-123.661) is within average values for comparable stocks, (1.909). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (15.038) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TXG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TXG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a life science technology company, which engages in building products to interrogate, understand and master biology
Industry MedicalNursingServices
Advertisement